Transforming the way scientists are treating the body’s response to diseases.

The goal of our toll-like receptor (TLR) agonist platform and clinical development program is to tap into the natural function of the immune system from within the tumor environment with our lead TLR9 agonist, IMO-2125, essentially giving the system a boost to affect the treated tumor as well as initiating a reaction from outside the tumor to provide for systemic treatment.

We have demonstrated pre-clinically and more recently clinically, that by combining Ipilimumab (an anti-CTLA4 antibody) , a currently approved treatment for metastatic melanoma, with our intratumoral IMO-2125, we can enable these therapies to have deeper and longer-lasting responses in patients who are refractory to anti-PD1 therapy.

Along with our research alliance partner, MD Anderson Cancer Center, we have recently completed enrollment in the dose escalation phase of our clinical trial of IMO-2125 in combination with Ipilimumab in PD-1 refractory metastatic melanoma patients. We’ll soon be selecting our dose and advancing to the Phase 2 portion of the trial which will enroll 21 patients at the selected dose.  We also are enrolling an arm in the trial to test the combination of IMO-2125 with Pemrolizumab and have plans to begin additional studies during 2017 to study IMO-2125 as a monotherapy and explore additional combination regimens and other tumor types.  For more information on this study, go to the U.S. FDA Clinical Trial Registry Website ,contact Idera at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.